|Security||RISE / Sit Rising Rate ETF (26923H101)|
|Institutional Shares||1,463,255 - 86.07%|
|Common Shares Outstanding||1,700,040 shares (as of 2018-03-31)|
|Institutional Value||$ 21,000 USD|
Institutional Stock Ownership and Shareholders
Sit Rising Rate ETF (NYSE:RISE) has 2 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,463,255 shares.
Largest shareholders include
Sit Investment Associates Inc, and UBS Group AG.
Sit Rising Rate ETF (NYSE:RISE) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|UBS Group AG||1,580||855||-45.89||38||21||-44.74|
|JANE STREET GROUP, LLC||87,101||0||-100.00||2,070||0||-100.00|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||9,254||0||-100.00||213||0||-100.00|
|SIT INVESTMENT ASSOCIATES INC||1,319,800||1,462,400||10.80|
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...
Related News Stories
Now that trade war concerns appear to have eased somewhat, decent Q1 earnings have started hitting the market and some upbeat economic readings are coming up, long-term U.S. treasury yields have started soaring. Yields on 10-year Treasury notes crossed the 2.9% mark on Apr 19, marking the one-month high.
Investors seeking momentum may have Sit Rising Rate ETF (RISE - Free Report) on radar now. The fund recently hit a new 52-week high. Shares of RISE are up approximately 9.3% from a 52-week low of $22.59/share.
While Wall Street braces for 10-Year Treasury yields to tick over 3 percent, one bond expert believes that will feel like a piece of cake compared to what may come next.
The inflation bogeyman has reared its head again, causing the first correction in nearly two years. (25-0)
The global economy has been on a solid footing with a rise in commodity prices, recovery in investment, boom in manufacturing and strong trade. The World Bank expects global economy to expand 3.1% this year while International Monetary Fund (IMF) projects global growth of 3.9% — the fastest expansion since 2011. The IMF attributes half of the growth to the new tax legislation in the United States. Amid surging global economic growth, investors are betting on an inflation comeback and the prospect of faster-than-expected monetary policy tightening. (13-0)
as of ET
Financial Charts by Fintel.io
|Industry||Commodity Contracts Brokers and Dealers|